SquareOne Medical, Inc. Becomes a Public Company, Completing a Reverse Merger Into E-18 Corporation

MINNEAPOLIS, MN--(Marketwire - July 09, 2009) -

SquareOne Medical, Inc., doing business as Protectus Medical Devices (“Protectus Medical Devices”), a privately held Nevada corporation, today announced the completion of its reverse merger into E-18 Corporation (OTCBB: ETEN), a publicly traded company. Protectus Medical Devices is now a wholly owned subsidiary of E-18 Corporation, which is trading on the OTC Bulletin Board under the symbol “ETEN.” The Company is in the process of changing its corporate name to Protectus Medical Devices, Inc. and is requesting a new symbol to better reflect its current business operations.

The Company’s lead product, the Protectus Safety Syringe, is a patented, automatic, self-sheathing hypodermic safety syringe. The Protectus Safety Syringe is designed to significantly reduce or eliminate accidental needlestick injuries that have plagued the healthcare workplace for decades. Healthcare workers may be pricked, scraped or injected by a needle before or after it has been injected and withdrawn from patients, potentially carrying infectious bloodborne diseases. The Company has received 510(k) permission from the FDA to manufacture and market its Safety Syringe in the U.S.

The Company is led by Dr. John Salstrom, President and CEO, a seasoned biotechnology and medical technology executive and entrepreneur with over 28 years experience in the industry. “The completion of this merger is a major milestone for Protectus Medical Devices,” Dr. Salstrom said. “Our Protectus Safety Syringe has several issued patents and, as the only fully automatic, self-sheathing hypodermic safety syringe that currently meets the functional definition of ‘Self-Sheathing’ mandated by the U.S. Federal Government, is uniquely positioned to solve a myriad of problems associated with needlestick injuries that have endangered healthcare workers and cost the healthcare system billions of dollars annually. These needlestick injuries have led to tens of thousands of cases of Hepatitis, HIV and other bloodborne diseases, many of which are fatal. Our mission is to dramatically enhance workplace safety for healthcare workers and patients and to have a significant impact on reducing healthcare costs (which exceed $3 billion dollars annually) related to needlestick injuries and their federally mandated follow-up and reporting activities.”

“The hypodermic syringe market alone is close to $5 billion of the $9 billion syringe marketplace worldwide. We have also adapted our cutting-edge, proprietary safety technology to other applications and will be introducing the Company’s family of safety syringe products in the near future,” Dr. Salstrom said. “We look forward to keeping shareholders and the public updated on our progress and encourage them to visit our web site at www.protectusmedical.com.”

About E-18 Corp.

E-18 Corp. develops and markets innovative safety medical percutaneous devices that, collectively, have the potential to dramatically reduce needlestick injuries for medical professionals worldwide. The Protectus Safety Syringe, the Company’s lead product, is the only fully automatic, self-sheathing hypodermic safety syringe that currently meets the functional definition of “Self-Sheathing” mandated by the U.S. Federal Government. None of the manufacturers of other devices on the market can make this claim. The Protectus Safety Syringe is the sole fully automatic, self-sheathing syringe in the nearly $5 billion global hypodermic syringe market. Protectus Medical Devices has successfully patented its automatic self-sheathing hypodermic safety syringe product, and, based on the results of full comparison clinical trials, the Protectus Safety Syringe (formerly the SquareOne Safety Syringe) has received the required 510(k) permission from the U.S. FDA to manufacture and market the device in the U.S. More information about the Company may be found at www.protectusmedical.com.

Forward-Looking Statements

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company’s expectations with regard to the future impact on the Company’s results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as “expects,” “intends,” “plans,” “may,” “could,” “should,” “anticipates,” “likely,” “believes” and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of E-18 Corp. can be found in the filings of E-18 Corp. with the U.S. Securities and Exchange Commission.